$70M Series C financing led by Deerfield Management; V-Wave also announced upcoming launch of the RELIEVE-HF pivotal study. V-Wave Ltd., an Israel-based company that has developed a proprietary, minimally invasive implanted interatrial shunt device for treating...
Early Experience in Class III Heart Failure Patients was Favorable. V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF), announced today the results of its first human implants were published in The Lancet....
Funding to support further development of V-Wave’s Unidirectional Interatrial Shunt for the treatment of Heart Failure. V-Wave Ltd. announced that it has completed a Series B financing of $28M. New investors included Johnson & Johnson Innovation – JJDC Inc.,...
NEAL EIGLER, MD, AND FRANK LITVACK, MD, AS V-WAVE CEO AND CHAIRMAN RESPECTIVELY, TO FURTHER DEVELOP AND COMMERCIALIZE V-WAVE UNIDIRECTIONAL SHUNT SYSTEM FOR THE TREATMENT OF HEART FAILURE Dr. Litvack received his MD from McGill University and was trained in Cardiology...
Recent Comments